Our Solutions


We have designed, conducted, analyzed, and reported on a large number of renal and hepatic impaired studies in recent years, across the spectrum of therapeutic areas. We partner with leading external sites to ensure that our renal and hepatic impaired patients have the specialized clinical oversight they need, and we leverage their databases to ensure we access the patient populations you need.

For renal impaired studies, we partner with Hôpital Maisonneuve-Rosemont (HMR), located near our Montreal clinic. HMR recruits and treats the severely and moderately impaired groups, and the Altasciences clinic completes with the mildly impaired and healthy matches. We have used this approach for more than 10 studies and usually conduct the clinical trial in less than three months.

For hepatic impaired studies, we work with leading sites in the U.S. and Canada. Depending on the need to include severely impaired patients, and the full inclusion/exclusion criteria, we conduct the studies with two to five sites. Our Project Managers simplify the multi-site process by providing one point of contact, and ensuring recruitment proceeds according to plan.

Consult our Renal and Hepatic Impaired Fact Sheet
Consult our Renal Impaired Fact Sheet

  • Single site option for renal studies with industry leading timelines
  • Network of sites with large hepatic impaired databases to meet your timelines


Our deep expertise and capabilities in a broad range of therapeutic areas encompasses preclinical and early clinical studies for both small molecules and biologics. We can manage your entire program, as well as provide comprehensive support research services and bioanalytical expertise.


Learn More

Working as a flexible, attentive extension of your team, we offer comprehensive drug development services to move your molecule forward.

Sign up for exclusive content

Join our list of 10,000+ VIP members and have access to our exclusive content.

You can unsubscribe at any time. For more details, please review our privacy policy.

Stay connected